## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.2% below STRENGTH zone (4.0-10.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-8.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($97.99)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Medtronic PLC $MDT Position Reduced by Panagora Asset Management Inc.**
- Source: MarketBeat | 20251202T123125 | Somewhat-Bullish | Relevance: 100%
- Panagora Asset Management Inc. significantly reduced its stake in Medtronic PLC by 2.7% in the second quarter of 2025. Despite this reduction, Medtronic reported strong quarterly earnings, beating analyst expectations with an EPS of $1.36 and revenue of $8.96 billion. The medical technology company also provided positive FY2026 EPS guidance, and analysts maintain a "Moderate Buy" rating for the stock.

**2. Medtronic begins U.S. commercial launch of the MiniMed™ 780G system with the Instinct sensor, made by Abbott**
- Source: PR Newswire | 20251202T140000 | Bullish | Relevance: 99%
- Medtronic has launched the MiniMed™ 780G system with the Instinct sensor, made by Abbott, in the U.S. This system offers automated insulin adjustments every five minutes and features the world's smallest, thinnest, and most discreet CGM sensor with up to 15 days of wear. This integration aims to provide a more seamless and personalized diabetes management experience for individuals with type 1 diabetes.

**3. Medtronic : welcomes Dr. Gerald Denny as Chief Medical Officer for Acute Care & Monitoring**
- Source: MarketScreener | 20251202T140800 | Somewhat-Bullish | Relevance: 99%
- Medtronic has announced the appointment of Dr. Gerald "Jeb" Denny as Chief Medical Officer for its Acute Care & Monitoring (ACM) business. This strategic hire aims to strengthen Medtronic's leadership in healthcare technology. This announcement was published on December 2, 2025.

**4. How Is Medtronic's Stock Performance Compared to Other Medical Devices Stocks?**
- Source: MSN | 20251130T230625 | Neutral | Relevance: 99%
- This article analyzes Medtronic's stock performance relative to its peers in the Medical Devices industry. It details Medtronic's year-to-date and 52-week returns, comparing them against the S&P 500, the industry average, and top-performing companies like Inspire Medical Systems and Inari Medical. The analysis indicates Medtronic has generally underperformed its industry.

**5. Grantham Mayo Van Otterloo & Co. LLC Trims Stake in Medtronic PLC $MDT**
- Source: MarketBeat | 20251201T100242 | Somewhat-Bullish | Relevance: 99%
- Grantham Mayo Van Otterloo & Co. LLC significantly reduced its stake in Medtronic PLC (NYSE:MDT) by 60% in the second quarter, selling over 101,000 shares. This comes even as Medtronic reported solid quarterly results, beating EPS and revenue estimates, and provided positive FY2026 guidance. Insider selling also occurred, with EVP Harry Skip Kiil trimming his holdings, while institutional investors collectively own a substantial portion of the company's stock.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Forward P/E 16.7x stretched relative to 8% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $129.2B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 16.7 |
| Current P/E | 18.1 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 10.6% to 2.2% (-8.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.8pp (needs >4.0% for momentum thesis). MRS_5 (-2.8%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.0% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.58), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.22% (CS: 79) | Neutral |
| RSI_14 | 61.6 | Neutral |
| MACD Histogram | 0.58 | Bullish |
| vs SMA20 | 1.040x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $102.03
- **Stop Loss:** $97.99 (4.0% risk)
- **Target:** $106.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 247
- **Position Value:** $25,201.41
- **Portfolio %:** 25.20%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*